Lysophosphatidic Acid is a Modulator of Cyst Growth in Autosomal Dominant Polycystic Kidney Disease

被引:7
作者
Blazer-Yost, Bonnie L. [1 ,4 ]
Blacklock, Brenda J. [2 ]
Flaig, Stephanie [1 ]
Bacallao, Robert L. [3 ,4 ]
Gattone, Vincent H. [1 ,4 ]
机构
[1] Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA
[2] Indiana Univ Purdue Univ, Dept Chem & Chem Biol, Indianapolis, IN 46202 USA
[3] Indiana Univ Sch Med, Div Nephrol, Indianapolis, IN USA
[4] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA
关键词
CFTR; Cystic fibrosis transmembrane regulator; LPA receptors; mpkCCD(cl4) cells; FLUID SECRETION; QUANTITATIVE-ANALYSIS; MOUSE MODEL; PROTEIN; CFTR; EPITHELIUM; TRANSPORT; AGONISTS; INJURY; HIT;
D O I
10.1159/000335857
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the slow growth of multiple fluid-filled cysts predominately in the kidney tubules and liver bile ducts. Elucidation of mechanisms that control cyst growth will provide the basis for rational therapeutic intervention. We used electrophysiological methods to identify lysophosphatidic acid (LPA) as a component of cyst fluid and serum that stimulates secretory Cl-transport in the epithelial cell type that lines renal cysts. LPA effects are manifested through receptors located on the basolateral membrane of the epithelial cells resulting in stimulation of channel activity in the apical membrane. Concentrations of LPA measured in human ADPKD cyst fluid and in normal serum are sufficient to maximally stimulate ion transport. Thus, cyst fluid seepage and/or leakage of vascular LPA into the interstitial space are capable of stimulating epithelial cell secretion resulting in cyst enlargement. These observations are particularly relevant to the rapid decline in renal function in late-stage disease and to the "third hit" hypothesis that renal injury exacerbates cyst growth. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:1255 / 1264
页数:10
相关论文
共 42 条
[1]   Lysophospholipid G protein-coupled receptors [J].
Anliker, B ;
Chun, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (20) :20555-20558
[2]   Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry [J].
Baker, DL ;
Desiderio, DM ;
Miller, DD ;
Tolley, B ;
Tigyi, GJ .
ANALYTICAL BIOCHEMISTRY, 2001, 292 (02) :287-295
[3]   Angiogenesis in autosomal-dominant polycystic kidney disease [J].
Bello-Reuss, E ;
Holubec, K ;
Rajarman, S .
KIDNEY INTERNATIONAL, 2001, 60 (01) :37-45
[4]  
Bens M, 1999, J AM SOC NEPHROL, V10, P923
[5]  
Blazer-Yost BL, 2010, PPAR RES, V2010, DOI [10.1155/2010/785369, 10.1155/2010/274376]
[6]   Approaches to testing new treatments in autosomal dominant polycystic kidney disease: Insights from the CRISP and HALT-PKD studies [J].
Chapman, Arlene B. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (04) :1197-1204
[7]   International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature [J].
Chun, Jerold ;
Hla, Timothy ;
Lynch, Kevin R. ;
Spiegel, Sarah ;
Moolenaar, Wouter H. .
PHARMACOLOGICAL REVIEWS, 2010, 62 (04) :579-587
[8]   The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro [J].
Davidow, CJ ;
Maser, RL ;
Rome, LA ;
Calvet, JP ;
Grantham, JJ .
KIDNEY INTERNATIONAL, 1996, 50 (01) :208-218
[9]   Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist [J].
East, James E. ;
Carter, Karen M. ;
Kennedy, Perry C. ;
Schulte, Nancy A. ;
Toews, Myron L. ;
Lynch, Kevin R. ;
Macdonald, Timothy L. .
MEDCHEMCOMM, 2011, 2 (04) :325-330
[10]   IN-VITRO FLUID SECRETION BY EPITHELIUM FROM POLYCYSTIC KIDNEYS [J].
GRANTHAM, JJ ;
YE, M ;
GATTONE, VH ;
SULLIVAN, LP .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (01) :195-202